AIMC Journal:
Experimental hematology & oncology

BACKGROUND: Bladder cancer is a common malignant tumor of the urinary system, and gemcitabine-based chemotherapy often fails because of drug resistance. Tumor heterogeneity, particularly copy number variations (CNVs) heterogeneity at the genomic leve...

Oncolytic viruses (OVs) represent a versatile platform for cancer immunotherapy, capable of selectively infecting and lysing tumor cells while triggering systemic antitumor immunity. However, their therapeutic efficacy remains limited by antiviral im...

BACKGROUND: Refined risk stratification before randomization is clinically important for reducing prognostic imbalance across study arms when evaluating novel therapies for glioblastoma. However, current artificial intelligence-assisted prognostic mo...